The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
💡 한 문장 핵심
양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
무작위 임상시험
5/5 보강
TL;DR
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
📑 코퍼스 인용 관계
· 인용됨 29
📑 인용한 논문 (6) ▾
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024. Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Be… Medicina (Kaunas, Lithuania) · 2025
- Integrating spatial transcriptomics and single-cell RNA-sequencing reveals epithelial cell… Genes & diseases · 2025
- Change in prostate tissue gene expression following finasteride or doxazosin administratio… Scientific reports · 2024
- A prospective evaluation of the effect of finasteride on prostate health index (phi). International urology and nephrology · 2023
연도별 인용 (2012–2026) · 합계 1,151
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
Urinary Tract Infections Management
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
양성전립선비대증(benign prostatic hyperplasia, BPH)에서 알파차단제(doxazosin), 5알파환원효소억제제(finasteride), 그리고 두 약제 병용요법이 장기적으로 임상적 진행 위험을 줄이는지 비교·평가하고자 했습니다.
【방법】
3,047명의 남성을 대상으로 위약·doxazosin·finasteride·병용요법 4군으로 나눈 이중맹검 장기 임상시험(평균 추적 4.5년)으로, AUA 증상점수 4점 이상 악화, 급성요폐, 요실금, 신기능저하, 반복 요로감염을 종합한 '임상적 진행'을 주요 지표로 삼았습니다.
【주요 결과】
전체 임상 진행 위험은 doxazosin 39%, finasteride 34% 감소했고, 병용요법은 66% 감소로 단독요법보다 유의하게 우월했습니다(모두 P<0.001~0.002). 급성요폐와 침습적 시술 필요성은 finasteride와 병용요법에서만 유의하게 감소했고(doxazosin은 효과 없음), 증상점수 개선은 세 군 모두 유의하되 병용요법이 가장 우수했습니다.
【임상적 시사점 (성형외과 의사 관점)】
본 연구는 비뇨의학 영역이라 성형외과 진료에 직접 적용되지는 않으나, finasteride가 안드로겐성 탈모(androgenetic alopecia) 치료에 흔히 처방되는 약제라는 점에서 참고 가치가 있습니다. 모발이식·탈모 클리닉을 함께 운영하는 경우, 중년 이상 남성에게 finasteride 처방 시 전립선 증상 변화(요폐·배뇨증상)와 PSA 수치 변동 가능성을 문진·모니터링하면 환자 안전 관리에 도움이 됩니다.
[BACKGROUND] Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.
[METHODS] We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.
[RESULTS] The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P=0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone.
[CONCLUSIONS] Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
[METHODS] We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.
[RESULTS] The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P=0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone.
[CONCLUSIONS] Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
- p-value P<0.001
- p-value P=0.002
- 추적기간 4.5 years
【연구 목적】 양성전립선비대증(benign prostatic hyperplasia, BPH)에서 알파차단제(doxazosin), 5알파환원효소억제제(finasteride), 그리고 두 약제 병용요법이 장기적으로 임상적 진행 위험을 줄이는지 비교·평가하고자 했습니다.
APA 7
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., Crawford, E. D., Diokno, A., Foley, J. P., Foster, H. E., Jacobs, S. C., Kaplan, S. A., Kreder, K. J., Lieber, M. M., Lucia, M. S., Miller, G. J., & ... (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.. The New England journal of medicine, 349(25), 2387-98. https://doi.org/10.1056/NEJMoa030656
Vancouver
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl. jour. medi.. 2003;349(25):2387-98. doi:10.1056/NEJMoa030656
AMA 11
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl. jour. medi.. 2003;349(25):2387-98. doi:10.1056/NEJMoa030656
Chicago
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., and .... 2003. "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia." The New England journal of medicine 349 (25): 2387-98. https://doi.org/10.1056/NEJMoa030656
MLA 9
McConnell, J. D., et al. "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia." The New England journal of medicine, vol. 349, no. 25, 2003, pp. 2387-98. doi:10.1056/NEJMoa030656.
PMID
14681504 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
- Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
- Finasteride for benign prostatic hyperplasia.
- Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
- Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?
- Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
- Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries…
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
- Comparison of clinical trials with finasteride and dutasteride.
- Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia:…
- The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, …
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate canc…
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024.
- A prospective evaluation of the effect of finasteride on prostate health index (phi).
- Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benig…
- Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia i…
- Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic h…
- Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hy…
- SRD5A2 and emerging therapies in androgen-driven disorders.
같은 제1저자의 인용 많은 논문 (5)
- The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
- Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
- Benign prostatic hyperplasia. Hormonal treatment.
- Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
- BPH: what really works?
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 양성 전립선 비대증에서 terazosin, finasteride 또는 병용 요법의 효능. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
- 여성 및 남성 안드로겐성 탈모 치료를 위한 근거기반(S3) 진료지침 - 요약본.